New data from a systematic review of randomized control trials indicated that moderate-to-severe psoriasis patients benefited from deucravacitinib as a first line treatment.
AbbVie s Skyrizi® shows long-term efficacy in psoriatic arthritis europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
AbbVie (ABBV) Reports New Data from Phase 3 Trials of SKYRIZI streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
/PRNewswire/ AbbVie (NYSE: ABBV) announced new, long-term data analyses of KEEPsAKE 1 and 2, Phase 3 trials evaluating SKYRIZI® (risankizumab, 150 mg) in.